AUG 20, 2026 · PHASE 1 TRIAL
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
ClinicalTrials.gov
Phase 1 study of a novel gastrointestinal agent in a small, healthy volunteer population with pharmacokinetic endpoints; no efficacy or safety results reported in this registry record.
Reported
Planned sample size56
Study phasePhase 1
Primary outcome measure 1Acetaminophen AUC, Baseline to Day 65